Dissecting the role of mTOR: Lessons from mTOR inhibitors

Guertin, 2007, Defining the role of mTOR in cancer, Cancer Cell, 12, 9, 10.1016/j.ccr.2007.05.008

Peterson, 2009, DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival, Cell, 137, 873, 10.1016/j.cell.2009.03.046

Frias, 2006, mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s, Curr. Biol., 16, 1865, 10.1016/j.cub.2006.08.001

Jacinto, 2006, SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity, Cell, 127, 125, 10.1016/j.cell.2006.08.033

Pearce, 2007, Identification of Protor as a novel Rictor-binding component of mTOR complex-2, Biochem. J., 405, 513, 10.1042/BJ20070540

Thedieck, 2007, PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis, PLoS One, 2, e1217, 10.1371/journal.pone.0001217

Woo, 2007, PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling, J. Biol. Chem., 282, 25604, 10.1074/jbc.M704343200

Sarbassov, 2004, Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton, Curr. Biol., 14, 1296, 10.1016/j.cub.2004.06.054

Sarbassov, 2005, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex, Science, 307, 1098, 10.1126/science.1106148

Garcia-Martinez, 2008, mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1), Biochem. J., 416, 375, 10.1042/BJ20081668

Hay, 2004, Upstream and downstream of mTOR, Genes Dev., 18, 1926, 10.1101/gad.1212704

Ma, 2009, Molecular mechanisms of mTOR-mediated translational control, Nat. Rev. Mol. Cell Biol., 10, 307, 10.1038/nrm2672

Pause, 1994, Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function, Nature, 371, 762, 10.1038/371762a0

De Benedetti, 2004, eIF-4E expression and its role in malignancies and metastases, Oncogene, 23, 3189, 10.1038/sj.onc.1207545

Sonenberg, 1998, The mRNA 5′ cap-binding protein eIF4E and control of cell growth, Curr. Opin. Cell Biol., 10, 268, 10.1016/S0955-0674(98)80150-6

Gingras, 1999, eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation, Annu. Rev. Biochem., 68, 913, 10.1146/annurev.biochem.68.1.913

Sonenberg, 2009, Regulation of translation initiation in eukaryotes: mechanisms and biological targets, Cell, 136, 731, 10.1016/j.cell.2009.01.042

Koromilas, 1992, mRNAs containing extensive secondary structure in their 5′ non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E, EMBO J., 11, 4153, 10.1002/j.1460-2075.1992.tb05508.x

Gingras, 2001, Hierarchical phosphorylation of the translation inhibitor 4E-BP1, Genes Dev., 15, 2852, 10.1101/gad.912401

Gingras, 1999, Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism, Genes Dev., 13, 1422, 10.1101/gad.13.11.1422

Mayer, 2004, mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability, Genes Dev., 18, 423, 10.1101/gad.285504

Raught, 2000, Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI, EMBO J., 19, 434, 10.1093/emboj/19.3.434

Codogno, 2005, Autophagy and signaling: their role in cell survival and cell death, Cell. Death Differ., 12, 1509, 10.1038/sj.cdd.4401751

Ganley, 2009, ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy, J. Biol. Chem., 284, 12297, 10.1074/jbc.M900573200

Hosokawa, 2009, Nutrient-dependent mTORC1 association with the ULK1–Atg13–FIP200 complex required for autophagy, Mol. Biol. Cell, 20, 1981, 10.1091/mbc.E08-12-1248

Jung, 2009, ULK–Atg13–FIP200 complexes mediate mTOR signaling to the autophagy machinery, Mol. Biol. Cell, 20, 1992, 10.1091/mbc.E08-12-1249

Porstmann, 2008, SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth, Cell Metab., 8, 224, 10.1016/j.cmet.2008.07.007

Kim, 2004, regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis, Diabetes, 53, 2748, 10.2337/diabetes.53.11.2748

Huffman, 2002, Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin, Proc. Natl. Acad. Sci. U. S. A., 99, 1047, 10.1073/pnas.022634399

Schieke, 2006, The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity, J. Biol. Chem., 281, 27643, 10.1074/jbc.M603536200

Cunningham, 2007, mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex, Nature, 450, 736, 10.1038/nature06322

Choi, 2002, The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase, EMBO Rep., 3, 988, 10.1093/embo-reports/kvf197

Land, 2007, Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif, J. Biol. Chem., 282, 20534, 10.1074/jbc.M611782200

Yokogami, 2000, Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR, Curr. Biol., 10, 47, 10.1016/S0960-9822(99)00268-7

Huang, 2008, The TSC1-TSC2 complex: a molecular switchboard controlling cell growth, Biochem. J., 412, 179, 10.1042/BJ20080281

Tee, 2002, Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling, Proc. Natl. Acad. Sci. U. S. A., 99, 13571, 10.1073/pnas.202476899

Vander Haar, 2007, Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40, Nat. Cell Biol., 9, 316, 10.1038/ncb1547

Sancak, 2007, PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase, Mol. Cell, 25, 903, 10.1016/j.molcel.2007.03.003

Fonseca, 2007, PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex, J. Biol. Chem., 282, 24514, 10.1074/jbc.M704406200

Wang, 2007, PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding, J. Biol. Chem., 282, 20036, 10.1074/jbc.M702376200

Oshiro, 2007, The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1, J. Biol. Chem., 282, 20329, 10.1074/jbc.M702636200

Fonseca, 2008, The binding of PRAS40 to 14-3-3 proteins is not required for activation of mTORC1 signalling by phorbol esters/ERK, Biochem. J., 411, 141, 10.1042/BJ20071001

Mamane, 2006, mTOR, translation initiation and cancer, Oncogene, 25, 6416, 10.1038/sj.onc.1209888

Sabatini, 2006, mTOR and cancer: insights into a complex relationship, Nat. Rev. Cancer, 6, 729, 10.1038/nrc1974

Inoki, 2003, TSC2 mediates cellular energy response to control cell growth and survival, Cell, 115, 577, 10.1016/S0092-8674(03)00929-2

Shaw, 2004, The LKB1 tumor suppressor negatively regulates mTOR signaling, Cancer Cell, 6, 91, 10.1016/j.ccr.2004.06.007

Feng, 2005, The coordinate regulation of the p53 and mTOR pathways in cells, Proc. Natl. Acad. Sci. U. S. A., 102, 8204, 10.1073/pnas.0502857102

Guertin, 2005, An expanding role for mTOR in cancer, Trends Mol. Med., 11, 353, 10.1016/j.molmed.2005.06.007

Barlund, 2000, Multiple genes at 17q23 undergo amplification and overexpression in breast cancer, Cancer Res., 60, 5340

Castellvi, 2006, Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer, Cancer, 107, 1801, 10.1002/cncr.22195

Rojo, 2007, 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis, Clin. Cancer Res., 13, 81, 10.1158/1078-0432.CCR-06-1560

Petricoin, 2007, Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival, Cancer Res., 67, 3431, 10.1158/0008-5472.CAN-06-1344

E Petroulakis, 2009, p53-Dependent translational control of senescence and transformation via 4E-BPs, Cancer Cell, 16, 439, 10.1016/j.ccr.2009.09.025

Dowling, 2009, Current status and challenges associated with targeting mTOR for cancer therapy, BioDrugs, 23, 77, 10.2165/00063030-200923020-00002

Mamane, 2004, eIF4E—from translation to transformation, Oncogene, 23, 3172, 10.1038/sj.onc.1207549

De Benedetti, 1999, eIF4E expression in tumors: its possible role in progression of malignancies, Int. J. Biochem. Cell Biol., 31, 59, 10.1016/S1357-2725(98)00132-0

Topisirovic, 2003, Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis, Mol. Cell Biol., 23, 8992, 10.1128/MCB.23.24.8992-9002.2003

Guertin, 2009, The pharmacology of mTOR inhibition, Sci. Signal., 2, pe24, 10.1126/scisignal.267pe24

Petroulakis, 2006, mTOR signaling: implications for cancer and anticancer therapy, Br. J. Cancer, 94, 195, 10.1038/sj.bjc.6602902

Chen, 1995, Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue, Proc. Natl. Acad. Sci. U. S. A., 92, 4947, 10.1073/pnas.92.11.4947

Kim, 2002, mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery, Cell, 110, 163, 10.1016/S0092-8674(02)00808-5

Oshiro, 2004, Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function, Genes Cells, 9, 359, 10.1111/j.1356-9597.2004.00727.x

Shor, 2008, A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis, Cancer Res., 68, 2934, 10.1158/0008-5472.CAN-07-6487

Sarbassov, 2006, Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB, Mol. Cell, 22, 159, 10.1016/j.molcel.2006.03.029

Rosner, 2008, Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1, Hum. Mol. Genet., 17, 2934, 10.1093/hmg/ddn192

Faivre, 2006, Current development of mTOR inhibitors as anticancer agents, Nat. Rev. Drug Discov., 5, 671, 10.1038/nrd2062

Liu, 2009, Targeting the phosphoinositide 3-kinase pathway in cancer, Nat. Rev. Drug. Discov., 8, 627, 10.1038/nrd2926

Kapoor, 2009, Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma, Cancer, 115, 3618, 10.1002/cncr.24409

Mita, 2008, Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies, J. Clin. Oncol., 26, 361, 10.1200/JCO.2007.12.0345

Choo, 2008, Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation, Proc. Natl. Acad. Sci. U. S. A., 105, 17414, 10.1073/pnas.0809136105

Huang, 2009, A complex interplay between Akt, TSC2 and the two mTOR complexes, Biochem. Soc. Trans., 37, 217, 10.1042/BST0370217

Alessi, 1997, 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase, Curr. Biol., 7, 776, 10.1016/S0960-9822(06)00336-8

Hresko, 2005, mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes, J. Biol. Chem., 280, 40406, 10.1074/jbc.M508361200

Jacinto, 2004, Mammalian OR complex 2 controls the actin cytoskeleton and is rapamycin insensitive, Nat. Cell. Biol., 6, 1122, 10.1038/ncb1183

Guertin, 2009, mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice, Cancer Cell, 15, 148, 10.1016/j.ccr.2008.12.017

Feldman, 2009, Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2, PLoS Biol., 7, e38, 10.1371/journal.pbio.1000038

Garcia-Martinez, 2009, Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR), Biochem. J., 421, 29, 10.1042/BJ20090489

Thoreen, 2009, An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1, J. Biol. Chem., 284, 8023, 10.1074/jbc.M900301200

Yu, 2009, Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin, Cancer Res., 69, 6232, 10.1158/0008-5472.CAN-09-0299

Choo, 2009, Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy, Cell Cycle, 8, 567, 10.4161/cc.8.4.7659

McMahon, 2002, The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin, Mol. Cell Biol., 22, 7428, 10.1128/MCB.22.21.7428-7438.2002

Hara, 2002, Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action, Cell, 110, 177, 10.1016/S0092-8674(02)00833-4

Nishiuma, 1998, Characterization of the phosphoproteins and protein kinase activity in mTOR immunoprecipitates, Biochem. Biophys. Res. Commun., 252, 440, 10.1006/bbrc.1998.9671

Yu, 2001, mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer, Endocr. Relat. Cancer, 8, 249, 10.1677/erc.0.0080249

Noh, 2004, Determinants of rapamycin sensitivity in breast cancer cells, Clin. Cancer Res., 10, 1013, 10.1158/1078-0432.CCR-03-0043

Neshat, 2001, Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR, Proc. Natl. Acad. Sci. U. S. A., 98, 10314, 10.1073/pnas.171076798

Wendel, 2006, Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo, Cancer Res., 66, 7639, 10.1158/0008-5472.CAN-06-0419

Dilling, 2002, 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin, J. Biol. Chem., 277, 13907, 10.1074/jbc.M110782200

Raymond, 2004, Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer, J. Clin. Oncol., 22, 2336, 10.1200/JCO.2004.08.116